Watchlist Price Alert

Beam Therapeutics Inc. (BEAM)

NASDAQ: BEAM · Real-Time Price · USD

17.43

0.18 (1.04%)

At close: May 09, 2025, 3:59 PM

18.20

4.45%

After-hours: May 09, 2025, 07:37 PM EDT

1.04% (1D)

Bid	17.38
Market Cap	1.75B
Revenue (ttm)	63.52M
Net Income (ttm)	-376.74M
EPS (ttm)	-4.61
PE Ratio (ttm)	-3.78
Forward PE	-3.6
Analyst	Buy

Ask	18.75
Volume	2,050,842
Avg. Volume (20D)	2,369,252
Open	17.40
Previous Close	17.25
Day's Range	17.37 - 18.75
52-Week Range	13.53 - 35.25
Beta	2.35

About BEAM

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BEAM

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BEAM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Beam Therapeutics has released their quartely earnings on May 6, 2025:

Revenue of $7.47M misses estimates by $7.21M, with 0.81% YoY growth.

EPS of -1.24 misses estimates by -0.07, with -2.48% YoY decline.

Why Price Moved

5 days ago

-19.32%

Beam Therapeutics shares are trading lower followi... Unlock content with Pro Subscription

2 months ago

-9.8%

Beam Therapeutics shares are trading lower after the company announced a $500 million offering.

News

4 days ago · zacks.com

BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates

Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.

5 days ago · fool.com

Why Beam Therapeutics Stock Tanked on Tuesday

Precision gene-editing company Beam Therapeutics (BEAM -19.68%) had a Tuesday to forget on the stock market. Following the release that morning of its latest set of quarterly results, the shares raced...

5 days ago · zacks.com

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.21 per share a year ago.

1 month ago · schaeffersresearch.com

Power Ranking Our Top Stock Picks of 2025

Subscribers to Chart of the Week received this commentary on Sunday, March 30.

1 month ago · invezz.com

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration.

1 month ago · zacks.com

BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance

The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.

1 month ago · seekingalpha.com

Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy

Recently, BEAM reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. Unfortunately, they concurrently announced a $500 million equity offering, which may have...

1 month ago · schaeffersresearch.com

3 Gene Therapy Stocks to Watch Amid Industry Turmoil

Sarepta Therapeutics Inc (NASDAQ:SRPT) is down 23.2% to trade at $77.86 at last check, and earlier hit a 52-week low of $75.06.

2 months ago · zacks.com

BEAM Down Despite Positive Initial Data From Genetic Disorder Study

Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency.

2 months ago · benzinga.com

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

On Monday, Beam Therapeutics Inc. BEAM announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 anti...

Load More News